Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Quantitative Proteomics: A Major Piece in the Precision Medicine Puzzle
Posted on December 22nd, 2017 by Betsy Davis in Pharma R&D
Our genetic make-up, where we live and how we live, are all important factors to consider when we are dealing with disease. For a very long time, medicine has mostly been designed to treat the sickness without much thought to the individual who has it. Continue reading “Quantitative Proteomics: A Major Piece in the Precision Medicine Puzzle” »
Considering lifestyle and environment to maximize the economic value of R&D
Posted on November 10th, 2017 by Dr Andrew A. Parsons in Pharma R&D
With an interest in systems approaches, I am always on the look-out for interesting papers in this area. A recent paper in Drug Discovery Today caught my eye for several reasons (1). The first was the extent of the problem with non-alcoholic liver disease. Continue reading “Considering lifestyle and environment to maximize the economic value of R&D” »
Why a reliable FAERS searching capability is essential for pharma companies
Posted on October 27th, 2017 by Sherry Winter in Pharmacovigilance
In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »
Snakes (aka Chutes) and Ladders – failures and opportunities
Posted on October 13th, 2017 by Dr Andrew A. Parsons in Pharma R&D
If there ever was a children’s game that would help prepare the next generation of pharmaceutical R&D scientists and researchers, it would be Snakes and Ladders (Chutes and Ladders in the US). Continue reading “Snakes (aka Chutes) and Ladders – failures and opportunities” »
